Dr Teresa Amaral reviews new guidelines for localized uveal melanoma, covering enucleation, radiotherapy nuances, and the current evidence on adjuvant systemic treatment. Medscape Oncology
Tag: Hematology-Oncology
Imaging and Staging Essentials in Uveal Melanoma
Dr Teresa Amaral reviews new uveal melanoma guidelines, focusing on AJCC 8th Edition staging, the Liverpool prognostic tool, and the essential role of BAP1 and PRAME expression. Medscape Oncology
ESMO Update: New Guidance for Rare Uveal Melanoma
Dr Teresa Amaral breaks down the essential new guidelines for uveal melanoma. Stay ahead of the latest standards in patient care. Medscape Oncology
Medscape Oncologist Compensation Report 2026
US oncologists report their 2025 compensation and satisfaction with it. Differences in doctor pay by gender, racial and ethnic group, and medical specialty are revealed. Medscape
IDEAYA and Servier’s Eye Cancer Drug Meets Trial Goal, Paving Way for FDA Application
IDEAYA Biosciences and French pharma company Servier said on Monday their combination drug for a type of eye cancer met the main goal of a mid-to-late-stage trial, sending… Reuters Health Information
PRAME TCR Therapy Delivers Breakthrough in Uveal Melanoma
Dr Teresa Amaral reviews ESMO 2025 data showing unprecedented response rates with PRAME-directed TCR therapy in metastatic uveal melanoma. Medscape Oncology
ESMO 2025: CheckMate 238 Update Reinforces Nivolumab Benefit
Dr Teresa Amaral discusses the 9-year update on CheckMate 238 presented at ESMO 2025. Medscape Oncology
Chemotherapy Drug Shortages Become Cancer-Care Reality
Shortages to backbone chemotherapy drugs are negatively affecting patient care, and more shortages are likely without policy solutions, experts say. Medscape Medical News
Targeted T-cell Therapy Beneficial in Rare Form of Melanoma
Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, despite them not being amenable to traditional immunotherapy, suggests trial. Medscape Medical News
Targeted T-Cell Therapy Beneficial in Rare Form of Melanoma
Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, despite them not being amenable to traditional immunotherapy, suggests trial. Medscape Medical News
Cancer Patients Request Financial Support Exceeding $5000
Researchers analyzed requests for assistance from patients with cancer enrolled in a novel digital support registry. Medscape Medical News
FDA Approves New ADC for Lung Cancer Treatment
Dr Mark Kris discusses datopotamab deruxtecan as a potent option post-osimertinib but warns of toxicity patterns unfamiliar to many lung oncologists. Medscape Oncology
Efficacy and Toxicity Seen With MIRV in Ovarian Cancer
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News
Kraft: The “Medaverse” Means New Roles for Clinicians
Working with a blend of AI tools and avatars, Daniel Kraft sees dramatic changes in how future clinicians will interact with patients. Medscape
‘Alarming Disparities’ in Cancer Trends and Shift to Women, Younger Adults
Annual cancer statistics report identifies persistent racial and ethnic disparities and increases in certain cancers in women and younger adults. Medscape Medical News
Olaparib Protects Patients From High-Risk Cancer Recurrences
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first patient in the phase 3 OlympiA trial was enrolled. Medscape Medical News
Eye Toxicities Are a Growing Concern With Certain ADCs
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop treatment, yet many oncologists are unaware of the risks, experts warned. Medscape Medical News
Trastuzumab Duocarmazine Tried in HER2+ Breast Cancer
Patients with unresectable locally advanced or metastatic HER2+ breast cancer were randomly assigned to receive trastuzumab duocarmazine or a physician’s choice. Medscape Medical News
Three vs Six Cycles of Chemo for Retinoblastoma
Participants were randomly assigned to receive either three or six cycles of CEV chemotherapy after enucleation. Medscape Medical News
Hereditary Amyloidosis: 5 Things to Know
The heterogeneity of hereditary amyloidosis can delay diagnosis and seriously affect prognosis and patient quality of life; these five things are need-to-know. Medscape Oncology